What Happened?
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it received U.S. Food and Drug Administration (FDA) approval for its generic Iron Sucrose Injection, a treatment for iron deficiency anemia. This injectable drug is a generic version of Venofer® and is used to treat iron deficiency anemia in patients with chronic kidney disease. The approval provides Amphastar access to a significant market, as sales for the brand-name equivalent were approximately $513 million in the U.S. for the twelve months ending in June 2025. The company announced plans to launch the product in the third quarter of 2025. This positive development follows the company's strong second-quarter earnings report from the prior week, where it posted an adjusted earnings per share of 85 cents, beating Wall Street estimates.
Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Amphastar Pharmaceuticals’s shares are somewhat volatile and have had 11 moves greater than 5% over the last year. But moves this big are rare even for Amphastar Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 19 days ago when the stock gained 5.5% on the news that a new trade agreement between the United States and Japan spurred a broad market rally. The positive sentiment swept across markets after it was announced the U.S. and Japan had reached a new trade deal. The agreement included a 15% tariff on Japanese goods imported into the U.S. and a commitment from Japan to invest $550 billion in the U.S. and open its markets to American cars and agricultural products. This development boosted investor confidence and contributed to a widespread rally, lifting stocks across many sectors. The Dow Jones Industrial Average and the S&P 500 both posted gains, creating a favorable environment that likely benefited individual stocks.
Amphastar Pharmaceuticals is down 27.2% since the beginning of the year, and at $26.46 per share, it is trading 50.5% below its 52-week high of $53.40 from November 2024. Investors who bought $1,000 worth of Amphastar Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,330.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
